Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan
Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
Anticancer Res. 2020 Apr;40(4):2373-2377. doi: 10.21873/anticanres.14206.
BACKGROUND/AIM: The clinical significance of surgery for secondary small intestinal non-Hodgkin's lymphomas (NHL) remains unknown. This study aimed to investigate the efficacy of resection for both primary and secondary small intestinal NHL.
Twenty patients with small intestinal lymphoma who underwent surgical resection at our Institute between 2009 and 2017 were retrospectively evaluated. The clinicopathological and surgery-related factors were reviewed. We also analyzed their surgical outcomes such as postoperative complications, perforation rate, and overall survival (OS).
In total, 13 (65%) and 7 (35%) patients had primary and secondary lymphomas, respectively. A total of 70% of patients were diagnosed with aggressive-type lymphomas. A total of 15 (75%) patients had Lugano system stage IV. Only one (5%) patient experienced postoperative grade II deep vein thrombosis and pulmonary embolism. The 3-year OS rate after surgery was 59.6%.
Surgical resection prior to chemotherapy is a feasible and safe therapeutic strategy for small intestinal NHL.
背景/目的：手术治疗继发性小肠非霍奇金淋巴瘤（NHL）的临床意义尚不清楚。本研究旨在探讨手术切除原发性和继发性小肠 NHL 的疗效。
回顾性分析 2009 年至 2017 年我院 20 例小肠淋巴瘤患者的临床病理和手术相关因素。分析手术相关并发症、穿孔率及总生存（OS）等手术结果。
共 13 例（65%）和 7 例（35%）患者分别为原发性和继发性淋巴瘤，70%的患者诊断为侵袭性淋巴瘤，15 例（75%）患者为 Lugano 系统 IV 期，仅 1 例（5%）患者术后发生 II 级深静脉血栓形成和肺栓塞。术后 3 年 OS 率为 59.6%。
化疗前手术切除是治疗小肠 NHL 的一种可行且安全的治疗策略。
